Nonsurgical periodontal treatment,
does it really help with Lower HbA1c and prevention of diabetic complications?
research showsThe grade is C with 46 points. The 2022 Cochrane review included 35 parallel randomized trials and 3,249 randomized participants. At three to four months, 30 trials and 2,443 analyzed participants gave an HbA1c difference of -0.43 percentage points (95% CI -0.59 to -0.28); at six months, 12 trials and 1,457 participants gave -0.30 (-0.52 to -0.08). Short-term lowering is supported, but HbA1c is a surrogate, follow-up was three to twelve months, and complication-event data were not verified.
ads claimThis does not mean gum treatment replaces diabetes medication or prevents complications. The evidence concerns a short-term laboratory change added to standard diabetes care in people who also have periodontitis.
Useful facts when choosing a product
- DPTT improved probing depth by 0.28 mm, attachment level by 0.25 mm, and bleeding sites by 13.1 percentage points versus control.
- DPTT's adjusted six-month HbA1c difference was -0.05 points (95% CI -0.23 to 0.12).
- Verdict 828 is B with 62 points for local chlorhexidine effects; this verdict evaluates full nonsurgical periodontal therapy against a diabetes surrogate.
Chamgap Semantic Classification Code
Candidate index · review held
P.nonsurgical-periodontal-treatment-centered-on-scaling-and-root-planing-in-people-with-diabetes-and-periodontitis.procedural.hba1c-and-prevention-of-diabetic-complications.prevent.UNKProcedures, devices and tests > Nonsurgical periodontal treatment centered on scaling and root planing in people with diabetes and periodontitis > Procedural > HbA1c and prevention of diabetic complications > Occurrence-prevention claim > Unknown
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Cochrane searched six databases through September 2021 and included 35 trials with 3,249 randomized participants. Follow-up ranged from three to twelve months; two trials were low risk overall, 14 high risk, and 19 unclear. The three-to-four-month analysis used 2,443 participants with outcome data and the six-month analysis 1,457. The source reports mean differences, sample sizes, and confidence intervals, which contain variance information, but it does not present one common pooled within-arm standard deviation for valid standardization of the aggregate estimate. DPTT NCT00997178 registered six-month HbA1c as primary, with masked laboratory and periodontal examiners. Recruitment stopped under a prespecified futility rule, and 514 participants were analyzed. DPTT had public NIDCR funding, while the wider trial set mixed no external funding, public support, and unreported sources.
Why this is classified as C (46)
Short-term HbA1c lowering is supported, but standardized magnitude cannot be calculated validly, the outcome is a surrogate, trials were brief and often bias-prone, and the largest trial was null, giving C with 46 points.
Counterpoint. The primary purpose of periodontal treatment is oral disease control. HbA1c is a possible added benefit, not a replacement for standard diabetes care.
Rejudgment record. Cross-check applied — Separated local periodontal improvement from HbA1c and verified analyzed denominators, pooled differences and intervals, standardization limits, the largest trial's registered primary failure, follow-up, bias, and funding
| Endpoint | S | Surrogate marker - laboratory or imaging measures |
| Replication | R1 | Single confirmatory trial |
| Independence | I1 | Mixed funding sources |
| Effect size | EX | The clinical size of the effect could not be judged |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Lower HbA1c at three to six months | C | Pooled differences were -0.43 and -0.30 points, but HbA1c is a surrogate. |
| Prevention of diabetic complications | ? | Trials lasted three to twelve months and did not establish complication events. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Simpson et al. Cochrane 2022 | Systematic review of 35 parallel randomized trials | 3,249 randomized; 2,443 analyzed at three to four months and 1,457 at six months | Included trials mixed no external, public, and unreported funding; the review had NIHR support | HbA1c at three to twelve months | Three to four months: -0.43 points (-0.59 to -0.28); six months: -0.30 (-0.52 to -0.08). | Decisive body of randomized evidence |
| Engebretson et al. DPTT 2013 | Multicenter single-masked randomized trial | 514 randomized, 257 per arm, with full imputed analysis | Public US NIH/NIDCR U01 grants | Registered primary outcome of six-month HbA1c change | Adjusted difference -0.05 points (-0.23 to 0.12), P=.55. | Null result from the largest rigorous trial |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-08-04).
Final verification and publication gate: Codex · Evidence date: 2026-08-04 · Corrections: none
Cite this verdict
[Chamgap] Nonsurgical periodontal treatment x lower HbA1c — Evidence Grade C·46. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/blood-sugar/periodontal-treatment-diabetes-hba1c/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.